Control Populations for Robust Biomedical Research
Control populations are essential for validating that signals detected in diseased specimens represent disease biology rather than confounding variables. MT Group has supported control population collections for over 20 years, providing pharmaceutical and biotechnology companies with carefully matched healthy donors and at-risk cohorts that serve as critical comparators in biomarker discovery, diagnostic development, and therapeutic research. Blood is the most commonly collected specimen type for control populations, though normal tissue controls are also available in select circumstances. MT Group works with you during study design to determine the most appropriate control strategy and assess feasibility for specific control specimen requirements.
Control Populations for Robust Biomedical Research
Control populations are essential for validating that signals detected in diseased specimens represent disease biology rather than confounding variables. MT Group has supported control population collections for over 20 years, providing pharmaceutical and biotechnology companies with carefully matched healthy donors and at-risk cohorts that serve as critical comparators in biomarker discovery, diagnostic development, and therapeutic research. Blood is the most commonly collected specimen type for control populations, though normal tissue controls are also available in select circumstances. MT Group works with you during study design to determine the most appropriate control strategy and assess feasibility for specific control specimen requirements.
Types of Control Populations
Healthy Controls
Healthy control subjects have no known history of the disease under study and serve as baseline comparators to establish normal biological ranges and validate disease-specific signals. MT Group collects healthy controls matched to disease populations by demographic factors including age, gender, ethnicity, and BMI, as well as lifestyle factors such as smoking status, alcohol consumption, and relevant medical history exclusions. Healthy controls undergo the same rigorous clinical data collection and specimen processing protocols as diseased cohorts, ensuring valid comparisons.
High-Risk & At-Risk Controls
High-risk and at-risk control populations are critical for demonstrating assay specificity by distinguishing true disease signals from conditions that mimic disease characteristics or represent precursor states. Examples include subjects with ductal carcinoma in situ (DCIS) or dense breast tissue as controls for breast cancer studies, lung nodules or COPD as controls for lung cancer research, and individuals with family histories of autoimmune diseases as controls for autoimmune condition studies. These at-risk populations help identify biomarkers that differentiate early-stage or high-risk conditions from established disease, supporting development of early detection assays and risk stratification tools.
Clinical Scenario Controls
Clinical scenario controls are subjects undergoing the same diagnostic or screening procedures as disease populations but without disease findings, providing matched clinical context for biomarker validation. Examples include subjects undergoing colonoscopy without findings of inflammatory bowel disease or colorectal cancer, women receiving mammograms with normal results, or individuals undergoing CT scans for lung cancer screening with no detected abnormalities. These controls are particularly valuable for liquid biopsy and diagnostic test development, as they represent the actual population that would be screened in clinical practice.
Biospecimen Types for Control Collections
Healthy Controls
Blood is the most commonly collected biospecimen type for control populations, available as fresh whole blood, plasma, serum, buffy coat, or PBMCs. Blood specimens from controls enable immune cell profiling, circulating biomarker analyses, proteomic and genomic comparisons, and establishment of normal reference ranges. Collections can accommodate various anticoagulants including EDTA, heparin, and citrate, as well as customized processing protocols. Control blood specimens undergo the same rigorous collection timing, processing, and quality standards as diseased population samples to ensure valid comparisons.
Normal Adjacent Tissue (NAT)
Normal adjacent tissue is collected from the same surgical resection as tumor tissue, providing patient-matched control tissue that accounts for individual genetic background and environmental exposures. NAT is particularly valuable when comparing diseased and non-diseased tissue from the same anatomic site within individual patients. These specimens can be processed as fresh overnight tissue, FFPE blocks, or frozen tissue depending on study requirements. Availability depends on surgical procedures and pathology release of sufficient tissue volume.
True Normal Tissues
True normal tissues from healthy donors without disease are available in limited quantities from elective surgical procedures. Skin specimens can be collected as 2" x 2" sections or punch biopsies (2mm or 3-4mm diameter) from healthy donors. Abdominal and breast adipose tissue is also available from subjects undergoing elective cosmetic or surgical procedures. Colonic pinch biopsies can be obtained during colonoscopy procedures.
Other Biospecimens
Additional biospecimen types including urine, stool, saliva, and other biofluids can be collected from control populations when relevant to specific disease comparisons. These non-invasive specimens are particularly useful for establishing baseline ranges in liquid biopsy development and for longitudinal monitoring of healthy and at-risk populations over time.
Control Collection Design
Demographics and Lifestyle Matching
Control subjects are matched to disease populations across key demographic and lifestyle variables to minimize confounding factors and isolate disease-specific signals. Matching parameters include age (exact age or age ranges), gender, ethnicity, geographic location, and BMI. Lifestyle factors such as smoking status (never, former, current smoker with pack-years), alcohol consumption patterns, diet, and physical activity levels can also be incorporated into matching criteria. MT Group works with you during study design to define which matching variables are most critical for your research objectives and implements rigorous enrollment protocols to ensure controls meet specified criteria.
Medical History Screening and Exclusions
Control populations require careful screening to exclude subjects with conditions that could confound research findings. Common exclusions include history of the disease under study, related diseases, active infections, recent vaccinations, immunosuppressive medications, and relevant comorbidities. For healthy control populations, broader exclusions may apply including any autoimmune disease, cancer history, chronic inflammatory conditions, or use of prescription medications. For at-risk controls, eligibility criteria are tailored to include the specific risk factors or precursor conditions relevant to the disease comparison while excluding established disease. MT Group's clinical data team validates medical history documentation to ensure controls meet study-specific exclusion criteria.
Timing Considerations
Specimen collection timing can significantly impact biological measurements, and control collections must account for the same timing variables as disease populations. Considerations include fasting status (overnight fasting vs. non-fasting), time of day for collection (morning vs. afternoon to control for circadian variation), menstrual cycle phase for premenopausal women, time relative to procedures (pre-colonoscopy vs. post-procedure), and seasonal factors when relevant. MT Group coordinates collection timing to match disease population protocols, ensuring valid comparisons across cohorts.
Single Timepoint vs. Longitudinal Controls
Control collections can be designed as single cross-sectional timepoints for comparison with diseased populations, or as longitudinal collections tracking healthy or at-risk subjects over time. Longitudinal control collections are particularly valuable for understanding normal biological variation, establishing stability of biomarkers in disease-free populations, and identifying subjects who progress from at-risk to diseased states. MT Group achieves 90%+ retention rates in longitudinal studies through proactive subject engagement and coordination with standard-of-care visit schedules.
Why Choose MT Group for Control Collections
Experience Designing Appropriate Control Strategies: MT Group brings over 20 years of experience helping researchers design control populations that address their scientific questions. We understand that poorly matched or inadequately characterized controls can undermine entire studies, so we invest time upfront asking detailed questions about your disease population, research objectives, and analytical approaches. This consultative process ensures control enrollment criteria appropriately match disease populations on critical variables while avoiding over-matching that reduces statistical power. Our team has designed control strategies across oncology, autoimmune diseases, metabolic conditions, and many other therapeutic areas.
Rigorous Enrollment Criteria Implementation: Control population enrollment requires the same precision as disease population recruitment—subjects must meet specific demographic profiles, lifestyle characteristics, and medical history criteria to serve as valid comparators. MT Group excels at implementing highly specific inclusion and exclusion criteria, ensuring our sites rigorously follow enrollment parameters. We conduct thorough feasibility assessments to provide honest projections about control availability rather than overpromising on difficult-to-recruit populations. Our sites understand the critical importance of adhering to detailed protocols for subject screening, specimen collection, and clinical data capture.
Comprehensive Clinical Data Validation: Control subjects require the same detailed clinical characterization as diseased populations to enable meaningful comparisons and account for potential confounding variables. MT Group's dedicated clinical data team meticulously reviews all case report forms for completeness and internal consistency before resolving queries with sites. This rigorous validation ensures accurate documentation of demographics, medical histories, lifestyle factors, medication use, and relevant laboratory values. We understand that comprehensive annotation of control populations is essential for interpreting research findings and maximizing the value of collected specimens.
Access to Diverse Control Populations: MT Group's established site network provides access to healthy donors, at-risk populations, and clinical scenario controls across diverse demographic groups and geographic regions. Our sites have experience recruiting control subjects who might otherwise be difficult to engage in research studies, including healthy individuals willing to undergo blood draws or tissue biopsies purely for research purposes. This broad access enables recruitment of control cohorts that truly reflect the diversity of disease populations being studied.
Quality Assurance & Services
Ethical procurement, rigorous reviews and full traceability ensure specimens you can trust.
IRB‑Approved Collections
All MT Group tissue collections are conducted under Institutional Review Board (IRB) approval, ensuring ethical procurement and full regulatory compliance. This commitment guarantees that every specimen is collected with proper informed consent and adheres to the highest standards of human subject research protections.
Quality Review
All blood products undergo a comprehensive quality review by the MT Group quality team prior to release. This systematic inspection includes hemolysis evaluation to ensure product integrity, verification of appropriate fill volumes to confirm compliance with established specifications, and thorough labeling examination to verify accuracy and completeness. This multi-point quality assessment serves as a critical control measure to ensure that only products meeting established quality standards are released.
Specimen Replacement Guarantee
MT Group stands behind the quality of every specimen delivered. If any tissue fails to meet specifications due to shipping issues, handling concerns, or quality parameters, we will replace the specimen at no additional cost, ensuring your research timelines and budgets remain on track.
Chain of Custody & Documentation
Comprehensive documentation accompanies each specimen, including collection details, processing protocols, storage conditions, and pathology reports. This complete chain of custody provides full traceability and the clinical context necessary for robust, reproducible research outcomes.
Why Leading Researchers Choose MT Group
Frequently Asked Questions
How closely must controls be matched to disease populations?
Matching requirements depend on your specific research objectives and the variables most likely to confound your analyses. Controls are regularly matched on age range and gender. More stringent matching can include ethnicity, BMI, smoking status, geographic location, and other lifestyle or clinical variables. MT Group works with you during study design to determine which matching criteria are essential versus desirable, balancing scientific rigor with enrollment feasibility. Over-matching can make recruitment difficult and may reduce statistical power, so we help identify the optimal matching strategy.
Can you recruit healthy controls willing to undergo tissue biopsies?
Yes, though availability is limited compared to blood-only collections. Some healthy donors are willing to undergo punch skin biopsies or other minimally invasive procedures for research purposes. True normal tissue is more commonly obtained from subjects undergoing elective surgical procedures where tissue can be collected opportunistically. MT Group conducts feasibility assessments to determine realistic recruitment expectations for tissue-based healthy control collections.
What screening is performed to verify controls are truly disease-free?
Control subjects are screened through medical history review, exclusion of relevant diagnoses from medical records, and self-reported health questionnaires. Additional laboratory testing or diagnostic procedures are generally not performed solely for research verification unless specified in the study protocol and budgeted accordingly. For clinical scenario controls undergoing procedures like colonoscopy or mammography, the clinical findings from those procedures serve as verification of disease-free status.
How are high-risk controls different from early-stage disease subjects?
High-risk or at-risk controls have characteristics that increase disease likelihood (such as DCIS, dense breast tissue, lung nodules, or family history) but do not have confirmed established disease. Early-stage disease subjects have received a definitive diagnosis even if the disease is mild or localized. The distinction is important for assay development—high-risk controls help demonstrate that biomarkers can distinguish true disease from elevated-risk conditions that might generate false positive signals.
Can control subjects be enrolled from the same sites as disease populations?
In some circumstances this is possible but not always. For example, healthy subjects are not typically seen by oncologists so it would not be feasible for most oncology sites to also enroll healthy subjects (this is possible at some integrated hospitals, however).
Are longitudinal control collections feasible?
Yes, longitudinal collections tracking healthy or at-risk subjects over time are feasible, though retention can be more challenging than with disease populations who have ongoing clinical care. MT Group achieves strong retention rates through proactive communication, coordination with subjects' existing healthcare visits when possible, and appropriate compensation for time and participation. Longitudinal controls are particularly valuable for understanding biomarker stability and identifying subjects who transition from at-risk to diseased states.
What is your minimum order for control population collections?
For prospective control collections, MT Group typically requires a minimum order of 10 subjects due to study startup investments including protocol development, site activation, and training.
How quickly can control subject enrollment begin?
Control population collections typically begin 2-4 weeks after receiving a purchase order, following the same activation timeline as disease collections. Nearly all collections fit under established umbrella IRB protocols. Actual enrollment timelines depend on the specificity of matching criteria—broadly defined healthy controls enroll faster than tightly matched or high-risk control populations with multiple eligibility requirements.
Contact MT Group
Complete the form below to discuss your tissue requirements with our experts.
No obligation consultation. Response within one business day.
